– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –

– Activity compares favorably with historical outcomes for TKI and HIF-2α monotherapies -–

– Combination was well tolerated and safety profile consistent with reported profiles of the individual agents –

– Findings support potential for darlifarnib to enhance activity of VEGFR-targeted therapies in second- and third-line RCC settings –

– Global, randomized Phase 1b study underway to establish recommended Phase 3 dose –

– Investor call scheduled for today, July 27, 2026, at 5:00 a.m. PT / 8:00 a.m. ET –